An observational study in Enhanced Recovery After Surgery and Emergency Surgery, sponsored by University of Milano Bicocca. Completed at 8 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by University of Milano Bicocca · Observational
This study defines a standardized protocol inspired to the ERAS philosophy for the peri-operative treatment of patients undergoing emergency abdominal surgery. Primary endpoint is the feasibility of the application of the standardized protocol; secondary endpoint is the safety
1,692 studies on the registry are indexed under Emergencies; 333 are open to participants now.
This study's enrollment of 589 is above the median of 353 across 714 observational studies indexed under Emergencies.
Browse Emergencies studies →University of Milano Bicocca is the lead sponsor of 124 studies on the registry; 48 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients undergoing emergency surgery for abdominal sepsis or occlusion and treated with bowel resection with or without anastomosis, intestinal bypass or adhesiolysis.
Exclusion Criteria:
All patients undergoing emergency abdominal surgery for infection or occlusion and treated with bowel resection with or without anastomosis; intestinal bypass or adhesiolysis
Other: Application of ERAS protocol
Application of a standardized ERAS protocol for the perioperative perioperative management of patients undergoing emergency surgery
Feasibility: % of application of post-operative ERAS items
Compliance to the standardize protocol for each item
Time frame: 30 days
Safety: complications rate within 30 days
Complication rate and mortality
Time frame: 30 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Milano Bicocca